Century Therapeutics, Inc. Common Stock
IPSCCentury Therapeutics, Inc. (IPSC) is a biotechnology company focused on developing allogeneic cell therapies for solid tumors and hematologic cancers. Leveraging its proprietary platform, Century aims to create off-the-shelf, living medicines using induced pluripotent stem cell (iPSC) technology to address unmet medical needs in cancer treatment.
Company News
Century Therapeutics has developed an innovative iPSC-derived beta islet therapy (CNTY-813) for Type 1 Diabetes, engineered with Allo-Evasionâ„¢ 5.0 technology to potentially provide durable glucose control without chronic immunosuppression. Preclinical data shows promising results in glucose normalization and immune protection.
Across the recent three months, 5 analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bu...
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
A more selective small-cap index has consistently outperformed the Russell 2000
The company is reshaping and expanding its oncology portfolio.
